Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
DNA vaccination can elicit the production of anti-tumor antibodies, thus obviating the need to continuously administer passive antibody. This vaccination strategy is particularly important where antibodies have proven to be effective anti-tumor agents. To amplify antibody responses against weak tumor antigens, we previously designed DNA-fusion vaccines incorporating tumor sequences linked to microbial genes. By using a safe idiotypic (Id) antigen from a B cell tumor fused to a fragment C (FrC) sequence from tetanus toxin, we induced both anti-Id and anti-FrC antibodies. It was important to determine whether the antigen itself, either injected or released from residual tumor cells, would boost the antibody response. Id protein not only failed to boost the response, but permanently and rapidly inhibited it by ablating Id-specific memory B cells. In contrast, an Id protein-FrC conjugate boosted both Id-specific and FrC-specific responses. Strikingly, the depletion of CD4+ T cells converted the Id protein-FrC conjugate vaccine into an inhibitor. These findings support the hypothesis that the activation of memory B cells by a DNA vaccine encoding a protein antigen, in the presence of the protein itself, depends completely on T cell help. Furthermore, by using knockout mice, we have shown that inhibition of the Id-specific memory B cells by the Id protein is largely independent of the FcgammaRIIB and, hence, independent of immune complexes. The principles revealed by using a DNA vaccine have implications for all cancer vaccines designed to induce and maintain antibody responses against weak autologous tumor antigens.
Savelyeva
Natalia
N
Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, Hampshire SO16 6YD, United Kingdom. ns1@soton.ac.uk
King
Catherine A
CA
Vitetta
Ellen S
ES
Stevenson
Freda K
FK
D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D000951:Antigens, Neoplasm / Q000235:genetics; D001402:B-Lymphocytes / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000494:pharmacology*; D003432:Cross-Linking Reagents; D007130:Immunoglobulin Idiotypes; D007156:Immunologic Memory; D008213:Lymphocyte Activation; D008211:Lymphocyte Cooperation; D008212:Lymphocyte Depletion; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology; D011947:Receptors, Antigen, B-Cell / Q000737:chemistry / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D019444:Vaccines, DNA / Q000235:genetics / Q000494:pharmacology*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D003432:Cross-Linking Reagents; D007130:Immunoglobulin Idiotypes; D009363:Neoplasm Proteins; D011947:Receptors, Antigen, B-Cell; D017452:Receptors, IgG; D019444:Vaccines, DNA